Roche licenses Alector's Parkinson's therapy in up‑to‑$1.27 billion deal
Roche agreed to pay Alector up to $1.27 billion for worldwide rights to the experimental Parkinson's drug AL050. The agreement includes a $100 million upfront cash payment and milestone payments that could total $1.17 billion. Under the deal, Roche’s Genentech unit will lead development, regulatory, manufacturing and commercialization, while Alector retains its brain‑delivery platform. The announcement sent Alector’s shares soaring in pre‑market trading.
Why it matters
Alector will receive up to $1.27 billion, providing substantial funding and validating its platform, which could accelerate its pipeline. Roche adds a brain‑penetrant enzyme replacement therapy to its neuro‑degeneration portfolio, potentially expanding its product pipeline.
Key facts
- 1Roche will pay up to $1.27 billion for global rights to Alector's AL050. finance.yahoo.com
- 2The deal includes a $100 million upfront payment. finance.yahoo.com
- 3Alector may receive additional milestone payments of up to $1.17 billion. finance.yahoo.com
- 4Genentech will be responsible for development, regulatory, manufacturing and commercialization. finance.yahoo.com
- 5Alector's shares rose 50% at market open to $2.73 on 5 October, compared with $1.81 at the close on 2 October. finance.yahoo.com
- 6The stock settled at $1.99 by the end of the day, a 9.9% day‑on‑day increase. finance.yahoo.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.